Posted by Michael Wonder on 03 Mar 2023
US FDA broadens indication for Verzenio (abemaciclib) in hormone receptor positive, HER2 negative, node positive, high risk early breast cancer
3 March 2023 - Approval supported by four-year data from the monarchE trial; Verzenio added to adjuvant endocrine therapy reduced the risk of recurrence by 35% compared to adjuvant endocrine therapy alone.
Eli Lilly today announced that the US FDA approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive, early breast cancer at a high risk of recurrence.
